NEW YORK (GenomeWeb News) – Expression Pathology plans to use a $148,000 grant from the National Cancer Institute to identify biomarkers and develop breast cancer diagnostic technology, the company said today.
Gaithersburg, Md.-based EPI said it will use the Small Business Innovation Research grant to use its microproteomics technologies to identify protein biomarkers of metastasis in primary breast cancer.
The company expects its Liquid Tissue sample preparation and Director laser microdissection will enable mass spectrometry-based proteomic profiling of archived formalin-fixed tissue.
“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions, and to identify new therapeutic targets and companion diagnostics to those targets,” explained EPI Chief Scientific Officer David Krizman.
The company also said in a statement that FFPE tissues are “a huge, untapped resource for discovery, validation, and measurement of valuable biomarkers of disease progression, drug response, and toxicity.”